Quarterly report pursuant to Section 13 or 15(d)

Acquisition - Additional Information (Detail)

v3.19.1
Acquisition - Additional Information (Detail) - USD ($)
3 Months Ended
Jun. 11, 2018
Feb. 28, 2019
Nov. 30, 2018
Business Acquisition [Line Items]      
Common stock par value   $ 0.01 $ 0.01
Customer Relationships [Member]      
Business Acquisition [Line Items]      
Useful lives   15 years  
Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member]      
Business Acquisition [Line Items]      
Aggregate consideration payable at closing under the Purchase Agreement $ 14,000,000    
Payment under asset purchase agreement $ 10,500,000    
Shares issued under asset purchase agreement 465,426    
Common stock par value $ 0.01    
Sale of stock price per share $ 7.52    
Percentage of earn out to be paid from gross revenues 75.00%    
Common stock deliver $ 200,000    
Common stock value 5,000,000    
Costs associated with the acquisition $ 580,000    
Discount rate 19.00%    
Long-term sustainable growth rate 3.00%    
Market royalty rate 1.00%    
Fair value of inventory $ 16,037,957    
Fair value of accounts receivable 188,019    
Fair value of prepaid expenses 68,867    
Short term deferred revenue 330,508    
Long term deferred revenue 1,074,898    
Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member] | Minimum [Member]      
Business Acquisition [Line Items]      
Amount of earn out to be paid from sale of public cord blood inventory $ 500,000    
Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member] | Brand [Member]      
Business Acquisition [Line Items]      
Useful lives 1 year    
Blood Bank Inc and Tianhe Stem Cell Biotechnologies Inc [Member] | Customer Relationships [Member]      
Business Acquisition [Line Items]      
Useful lives 30 years